Cadila Pharmaceuticals filgrastim
Filgrastim biosimilar developed by Cadila Pharmaceuticals. Reference product Neupogen.
About Cadila Pharmaceuticals filgrastim
Cadila Pharmaceuticals received its filgrastim permission in India in October 2013, with a permission for the drug substance in 2016. Cadila Pharmaceuticals is a separate company from Zydus, which was formerly Cadila Healthcare.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Cadila Pharmaceuticals filgrastim holds an approval, these are the other filgrastim biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 2 | Gennova Biopharmaceuticals (Gennova filgrastim), Lupin (Lupin filgrastim) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Cadila Pharmaceuticals: Cadila Pharmaceuticals human insulin.
Chronology
- CDSCOOct 2013CDSCO permission granted
Sources
S014CDSCO, permissions granted in Form 46 and 46A, to 2019 Primary (regulator)
Planning filgrastim biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant